Explore the vast range of titles available.

Intra-operative and post-operative bleeding is not common in advanced ovarian cancer surgery. Nevertheless, a multidisciplinary major hemorrhage protocol should be adopted by any center performing cytoreductive procedures. Surgical, pharmacological, and interventional radiology options should be part of the armamentarium, depending on each individual situation, timing, and available resources (Figure 1).

The European Society of Gynaecological Oncology (ESGO) developed and established for the first time in 2016, and updated in 2020, quality indicators for advanced ovarian cancer surgery to audit and improve clinical practice in Europe and beyond. As a sequela of the continuous effort to improve oncologic care in patients with ovarian cancer, ESGO issued in 2018 a consensus guidance jointly with the European Society of Medical Oncology addressing in a multidisciplinary fashion 20 selected key questions in the management of ovarian cancer, ranging from molecular pathology to palliation in primary and relapse disease. In order to complement the above achievements and consolidate the promoted systemic advances and surgical expertise with adequate peri-operative management, ESGO developed, as the next step, clinically relevant and evidence-based guidelines focusing on key aspects of peri-operative care and management of complications as part of its mission to improve the quality of care for women with advanced ovarian cancer and reduce iatrogenic morbidity. To do so, ESGO nominated an international multidisciplinary development group consisting of practicing clinicians and researchers who have demonstrated leadership and expertise in the care and research of ovarian cancer (18 experts across Europe). To ensure that the guidelines are evidence based, the literature published since 2015, identified from a systematic search, was reviewed and critically appraised. In the absence of any clear scientific evidence, judgment was based on the professional experience and consensus of the development group. The guidelines are thus based on the best available evidence and expert agreement. Prior to publication, the guidelines were reviewed by 117 independent international practitioners in cancer care delivery and patient representatives.

There is a rich program of forward physics measurements within the CMS Collaboration covering a wide range of topics. In many cases there is a connection to quantities and effects relevant for very high energy cosmic ray interactions. Some of the recent measurements in the fields of exclusive final states, low-pT inclusive and diffractive cross sections, underlying event, multiparton interactions, double parton scattering, final state particle correlations and minimum bias results are briefly summarized here.

Current and future challenges in astroparticle physics require novel simulation tools to achieve higher precision and more flexibility. For three decades the FORTRAN version of CORSIKA served the community in an excellent way. However, the effort to maintain and further develop this complex package is getting increasingly difficult. To overcome existing limitations, and designed as a very open platform for all particle cascade simulations in astroparticle physics, we are developing CORSIKA 8 based on modern C++ and Python concepts. Here, we give a brief status report of the project.

(1) Pions produced in the development of extended atmospheric cosmic ray air showers subsequently decay to muons. The measured yield of those muons is generally underestimated by current phenomenological models and event generators optimized for cosmic ray physics. The importance of those disagreements motivates the feasibility studies for testing these models at the Large Hadron Collider (LHC) energies, at the highest center-of-mass energies achievable in a laboratory. The interaction of a nucleus and a virtual pion created in a charge exchange reaction at the LHC is a similar process to those contributing to the development of air showers in case of cosmic rays. The crucial problem of such an analysis is the selection of charge exchange events with the highest possible efficiency and high purity from proton–proton collisions at the LHC. (2) For this we consider distributions of various measurable quantities given by event generators commonly used in cosmic ray physics. (3) We examine the expected distributions of energy deposited in different calorimeters of an LHC experiment. We consider the geometrical acceptance and energy resolution of the detectors at the Compact Muon Solenoid (CMS) experiment, as an example. We determine a working point cut from the various options for event selection, and compare signal and background predictions using different models for a representative simple observable, such as average transverse momentum or charge particle yield. (4) A set of event selection cuts along these considerations is proposed, with the aim of achieving optimal efficiency and purity.

Background Overall survival remains poor in older patients with acute myeloid leukemia (AML) with less than 10% being alive after 5 years. In recent studies, a significant improvement in event-free, relapse-free and overall survival was shown by adding gemtuzumab ozogamicin (GO), a humanized antibody-drug conjugate directed against CD33, to intensive induction therapy once or in a sequential dosing schedule. Glasdegib, the small-molecule inhibitor of smoothened (SMO), also showed improved overall survival in patients not eligible for intensive chemotherapy when combined with low-dose cytarabine compared to low-dose cytarabine alone. These findings warrant further investigations in the phase III GnG trial. Methods/Design This is a randomized phase III trial with measurable residual disease (MRD) after induction therapy and event-free survival (EFS) as primary endpoints. The two research questions are addressed in a 2 by 2 factorial design. Patients age 60 years and older are upfront randomized 1:1 in one of the two induction arms: GO administered to intensive induction therapy on days 1,4, and 7 versus GO administered once on day 1 (GO-147 versus GO-1), and double-blinded 1:1 in one of the subsequent treatment arms glasdegib vs. placebo as adjunct to consolidation therapy and as single-agent maintenance therapy for six months. Chemotherapy backbone for induction therapy consists of standard 7 + 3 schedule with cytarabine 200 mg/m 2 continuously days 1 to 7, daunorubicin 60 mg/m 2 days 1, 2, and 3 and high-dose cytarabine (1 g/m 2 , bi-daily, days 1, 2, and 3) for consolidation therapy. Addressing two primary endpoints, MRD-negativity after induction therapy and event-free survival (EFS), 252 evaluable patients are needed to reject each of the two null hypotheses at a two-sided significance level of 2.5% with a power of at least 85%. Ethics and dissemination Ethical approval and approvals from the local and federal competent authorities were granted. Trial results will be reported via peer-reviewed journals and presented at conferences and scientific meetings. Trial status Protocol version: 1st version 20.10.2020, no amendments yet. Study initiation on February 16, 2021. First patient was recruited on April 1st. Trial registration ClinicalTrials.gov NCT04093505 ; EudraCT 2019-003913-32. Registered on October 30, 2018.

This document is devoted to the description of advances in the generation of high-quality random numbers for CORSIKA 8, which is being developed in modern C++17 and is designed to run on modern multi-thread processors and accelerators. CORSIKA 8 is a Monte Carlo simulation framework to model ultra-high energy secondary particle cascades in astroparticle physics. The aspects associated with the generation of high-quality random numbers on massively parallel platforms, like multi-core CPUs and GPUs, are reviewed and the deployment of counter-based engines using an innovative and multi-thread friendly API are described. The API is based on iterators providing a very well known access mechanism in C++, and also supports lazy evaluation. Moreover, an upgraded version of the Squares algorithm with highly efficient internal 128 as well as 256 bit counters is presented in this context. Performance measurements are provided, as well as comparisons with conventional designs are given. Finally, the integration into CORSIKA 8 is commented.

Published data describing the efficacy and safety of autologous stem-cell transplantation (autoSCT) in post-transplant lymphoproliferative disorders (PTLD) is limited to case reports. This is a retrospective analysis of 21 patients reported to the EBMT registry who received an autoSCT for PTLD post solid organ transplant (SOT). Median age at autoSCT was 47 (range: 22–71) years. The commonest SOTs were kidney (48%) and liver (24%). Commonest histologies included DLBCL-type PTLD (14/21) and plasmacytoma-like PTLD (3/21). Patients received a median of two lines of therapy (range: 1–4) pre-autoSCT. ECOG performance status pre-autoSCT was 0 in 14% and 1 in 86%. Remission status pre-autoSCT was CR 47% and PR 38%. BEAM conditioning was used in 57% and high-dose melphalan in 10%. The median follow-up post-autoSCT was 64 months for alive patients. 3-year PFS was 62% [95% confidence interval (CI) 44–87%] and 3-year OS was 61% [95% CI:43–86]. There were 12 deaths, including four related to autoSCT. 100-day non-relapse-mortality (NRM) was 14% and 1-year NRM was 24%. This study suggests that autoSCT, although feasible and with potential therapeutic activity, is associated with a high NRM, primarily driven by infectious toxicity. A multi-disciplinary approach, expert microbiological input and stringent patient selection are required to optimise outcomes.

The CORSIKA 8 project is an international collaboration of scientists working together to deliver the most modern, flexible, robust and efficient framework for the simulation of ultra-high energy secondary particle cascades in matter. The main application is for cosmic ray air shower simulations, but it can also be applied to other problems in astro(particle)-physics, particle physics and nuclear physics. Besides a comprehensive and state-of-the-art collection of physics models as well as algorithms relevant for the field, also all possible interfaces to hardware acceleration (e.g. GPU) and parallelization (vectorization, multi-threading, multi-core) will be provided. We present the status and roadmap of this project. This code will soon be available for novel explorative studies and phenomonological research, and at the same time for massive productions runs for experiments.

The simulation of hadronic interactions is of fundamental importance for the analysis of extensive air showers. The details of the relation between the measurement of hadronic interactions at accelerators and the impact on the air shower development is very difficult to evaluate. Several possibilities to study this relation are presented here.